ArticleNeurological research and practice2026
Association of oral anticoagulation persistence and health-related quality of life in stroke survivors with atrial fibrillation: long-term results of the Berlin atrial fibrillation registry.
Article in Neurological research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPersistence to oral anticoagulation (OAC) is crucial to prevent recurrent stroke in patients with atrial fibrillation (AF). Little is known about the association of OAC intake, persistence to OAC, and type of OAC with health-related quality of life (HRQoL) in stroke survivors with AF.
methodsThis retrospective analysis of the multicenter Berlin Atrial Fibrillation Registry included 1,042 patients with acute ischemic stroke or transient ischemic attack (TIA) and AF. HRQoL data were measured at 3,12,24 and 36 months after stroke/TIA using the EQ-5D-3 L questionnaire (including EQ-Index and EQ-VAS). Associations between OAC status, persistence to and type of OAC (direct oral anticoagulants (DOACs) against vitamin K antagonists (VKAs)) at 12 and up to 36 months with HRQoL were examined using multivariable linear models.
resultsOverall, 842 patients completed the 12-months follow-up and 437 patients the 36-months follow-up. After 12 months, OAC intake was associated with higher EQ-VAS scores (β = 6.70, p = 0.017), although this effect was not observed up to 36 months (ß= -3.67, p = 0.075). Non-persistence to OAC was associated with lower EQ-VAS scores at 12 (ß= -6.25, p = 0.004) and 36 months (ß= -5.39, p < 0.001). No evidenve of a statistically significant difference in HRQoL was found between patients persistent to DOACs and those persistent to VKAs. EQ-Index values were not statistically significantly affected.
conclusionNon-persistence to OAC was associated with reduced EQ-VAS up to 36 months after stroke. Notably, no evidence of a statistically significant difference regarding HRQOL was found between patients persistent on DOAC or VKA. Ensuring long-term persistence to OAC may support HRQoL in stroke survivors with AF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.